CA
NZ
UK
AU
IND
US
…
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Fisher & Paykel Healthcare designs and manufactures non-invasive respiratory care devices and related consumables for hospital and homecare settings. Long-term growth may be supported by aging populations, rising chronic respiratory disease prevalence and expansion of home-based therapies, while consumables provide recurring revenue that could support predictability. The company appears positioned in a specialized niche with technology-led products that may appeal to investors seeking exposure to medical-device demand.
Key risks include regulatory and reimbursement changes, competition from larger medtech firms, and supply-chain or currency disruptions that could pressure margins and growth.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | 636.10M | 503.30M | 235.70M | 328.00M | 504.20M |
| Net income | 471.91M | 377.20M | 132.60M | 250.30M | 376.90M |
| Selling general administrative | - | 534.40M | 492.80M | 431.90M | 393.10M |
| Selling and marketing expenses | - | 534.40M | 492.80M | 431.90M | 393.10M |
| Gross profit | 1511.63M | 530.20M | 1044.40M | 945.90M | 1013.40M |
| Reconciled depreciation | - | 139.90M | 114.30M | 99.00M | 96.00M |
| Ebit | 671.86M | 514.40M | 353.40M | 334.70M | 509.10M |
| Ebitda | 831.61M | 654.30M | 444.80M | 433.70M | 605.10M |
| Depreciation and amortization | 159.75M | 139.90M | 91.40M | 99.00M | 96.00M |
| Operating income | 671.86M | -371.00M | 353.40M | 310.80M | 468.28M |
| Other operating expenses | 1684.17M | 1651.30M | 1389.40M | 34.05M | 76.69M |
| Interest expense | 10.37M | 11.10M | 18.20M | 6.70M | 4.90M |
| Tax provision | - | 126.10M | 103.10M | 77.70M | 127.30M |
| Interest income | - | 4.30M | 3.30M | 2.60M | 2.60M |
| Net interest income | - | -6.80M | -14.90M | -4.10M | -2.30M |
| Income tax expense | 164.19M | 126.10M | 103.10M | 77.70M | 127.30M |
| Total revenue | 2356.03M | 1280.30M | 1742.80M | 1588.60M | 1642.40M |
| Total operating expenses | 839.77M | 901.20M | 691.00M | 705.20M | 643.10M |
| Cost of revenue | 844.40M | 750.10M | 698.40M | 642.70M | 629.00M |
| Total other income expense net | -35.76M | 874.30M | -117.70M | -7.60M | 40.20M |
| Net income from continuing ops | - | 377.20M | 132.60M | 250.30M | 376.90M |
| Net income applicable to common shares | - | - | - | 250.30M | 376.90M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 2874.38M | 2550.80M | 2281.70M | 2204.50M | 2107.00M |
| Intangible assets | 73.23M | 82.10M | 88.40M | 85.60M | 86.80M |
| Other current assets | 21.15M | - | 45.30M | 68.90M | 64.70M |
| Total liab | 743.57M | 660.40M | 522.60M | 451.10M | 427.30M |
| Total stockholder equity | 2130.80M | 1890.40M | 1759.10M | 1753.40M | 1679.70M |
| Other current liab | 411.27M | - | 256.40M | 230.90M | 231.64M |
| Common stock | 501.53M | - | 404.00M | 303.70M | 261.20M |
| Capital stock | - | 468.60M | 404.00M | 303.70M | 261.20M |
| Retained earnings | 1453.31M | 1226.60M | 1095.00M | 1200.50M | 1181.20M |
| Other liab | - | - | - | 36.80M | 36.10M |
| Other assets | - | - | - | 196.20M | 174.40M |
| Cash | 464.46M | 264.50M | 82.00M | 121.00M | 89.90M |
| Total current liabilities | 501.42M | 500.40M | 385.00M | 289.80M | 303.90M |
| Current deferred revenue | - | - | - | -5.40M | 1.46M |
| Net debt | -317.29M | - | 107.10M | 24.80M | 14.40M |
| Short term debt | 33.04M | - | 96.20M | 21.30M | 17.00M |
| Short long term debt | - | 64.00M | 78.50M | 4.20M | 5.30M |
| Short long term debt total | 147.16M | - | 189.10M | 145.80M | 104.30M |
| Other stockholder equity | -5.24M | - | - | -1407.29M | -1335.93M |
| Property plant equipment | - | - | - | 1148.20M | 957.80M |
| Total current assets | 1160.59M | 935.40M | 704.90M | 774.20M | 887.90M |
| Net tangible assets | - | - | - | 1667.80M | 1592.90M |
| Short term investments | - | - | - | 0.47M | 200.00M |
| Net receivables | 345.30M | 267.30M | 257.20M | 218.50M | 174.40M |
| Long term debt | - | - | 35.70M | 79.10M | 63.00M |
| Inventory | 329.68M | 342.90M | 320.40M | 365.80M | 358.90M |
| Accounts payable | 57.11M | 52.90M | 32.40M | 43.00M | 53.80M |
| Accumulated other comprehensive income | 181.21M | - | 260.10M | 249.20M | 237.30M |
| Non currrent assets other | - | - | 55.90M | 99.62M | 90.81M |
| Non current assets total | 1713.79M | 1615.40M | 1576.80M | 1430.30M | 1219.10M |
| Capital lease obligations | - | 89.30M | 74.90M | 62.50M | 36.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | - | -103.00M | -339.00M | -11.30M | 80.30M |
| Change to liabilities | - | - | - | -19.00M | -5.70M |
| Total cashflows from investing activities | -196.62M | -103.00M | -339.00M | -11.30M | -89.50M |
| Net borrowings | - | -56.90M | 30.60M | -4.40M | -14.10M |
| Total cash from financing activities | -278.71M | -268.20M | -128.70M | -197.10M | -235.80M |
| Net income | 471.91M | 377.20M | 132.60M | 234.17M | 349.08M |
| Change in cash | 173.44M | 179.30M | -35.90M | 32.20M | -0.80M |
| Begin period cash flow | 291.02M | 80.90M | 116.80M | 84.60M | 85.40M |
| End period cash flow | 464.46M | 260.20M | 80.90M | 116.80M | 84.60M |
| Total cash from operating activities | 668.03M | 548.60M | 429.60M | 222.85M | 300.36M |
| Issuance of capital stock | - | 3.10M | 3.00M | 3.00M | 3.20M |
| Depreciation | 159.75M | - | 109.10M | 87.85M | 80.30M |
| Other cashflows from investing activities | - | -29.40M | -22.20M | - | - |
| Dividends paid | 254.14M | -195.90M | -145.50M | -195.70M | -224.90M |
| Change to inventory | 15.61M | -22.50M | 45.40M | -6.46M | -81.78M |
| Change to account receivables | -28.61M | -45.10M | -38.50M | -40.51M | 48.62M |
| Sale purchase of stock | - | - | - | 137.50M | 7.50M |
| Other cashflows from financing activities | -21.56M | -18.50M | -16.80M | -14.40M | -14.00M |
| Change to netincome | - | - | - | -41.90M | -107.10M |
| Capital expenditures | 174.06M | 103.00M | 339.00M | 211.30M | 169.80M |
| Change in working capital | 16.12M | -67.60M | 6.90M | -46.97M | -33.16M |
| Stock based compensation | - | - | 10.80M | 8.42M | 7.50M |
| Other non cash items | 24.07M | 616.20M | 170.20M | -99.17M | -129.02M |
| Free cash flow | 493.97M | 445.60M | 90.60M | 11.55M | 130.56M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FPH Fisher & Paykel Healthcare Corporation Ltd |
0.31 0.80% |
39.20 | 55.56 | 48.54 | 9.91 | 12.92 | 11.78 | 33.96 |
| RMD Resmed Inc |
0.14 0.40% |
34.75 | 21.77 | 19.57 | 8.49 | 5.53 | 5.50 | 14.10 |
| ANN Ansell Ltd |
0.14 0.31% |
45.66 | 21.27 | 22.73 | 2.99 | 2.16 | 2.24 | 12.03 |
| NAN Nanosonics Ltd |
-0.06 2.03% |
2.89 | 49.17 | 78.12 | 4.33 | 4.02 | 3.64 | 24.30 |
| AHC Austco Healthcare Ltd |
-0.01 3.64% |
0.27 | 13.75 | 16.31 | 1.09 | 1.63 | 0.94 | 5.71 |
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
| Name | Title | Year Born |
|---|---|---|
| Mr. Lewis G. Gradon | MD, CEO & Exec. Director | 1961 |
| Ms. Lyndal York | Chief Financial Officer | NA |
| Dr. Andrew Somervell | VP of Products & Technology | NA |
| Hayden Brown | Investor Relations Mang. | NA |
| Karen Knott | Gen. Mang. of Corp. Communications | NA |
| Mr. Paul N. Shearer B.Com. | Sr. VP of Sales & Marketing | NA |
| Ms. Nicola Talbot | VP of HR | NA |
| Mr. Jonathan Rhodes | VP of Supply Chain, Facilities & Sustainability | NA |
| Mr. Marcus Driller | VP of Corp. & Company Sec. | NA |
| Chris Crone | Gen. Mang. of Airvo Optiflow | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...